Protocol Ledger

NCT04870333 · Phase II/III · COMPLETED

PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V

Interventional Phase II/III clinical trial protocol NCT04870333 sponsored by Cambridge University Hospitals NHS Foundation Trust in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-02-19 Enrollment: 2,240 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04870333
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)2,240 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04870333
Protocol FieldVerified Registry Value
NCT IdentifierNCT04870333
Consolidated Lead SponsorCambridge University Hospitals NHS Foundation Trust
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II/III
Overall Recruitment StatusCOMPLETED
Registered Enrollment2,240 participants (ACTUAL)
Registered Start Date2021-02-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04870333
Hospital Research SiteLocationSite Profile
University Hospitals Birmingham NHS Foundation TrustBirmingham, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI